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Abstract
In human immune system, V(D)J recombination produces an enormously large repertoire of immunoglobulins (Ig) so that
they can tackle different antigens from bacteria, viruses and tumor cells. Several studies have demonstrated the utility of
next-generation sequencers such as Roche 454 and Illumina Genome Analyzer to characterize the repertoire of
immunoglobulins. However, these techniques typically require separation of B cell population from whole blood and
require a few weeks for running the sequencers, so it may not be practical to implement them in clinical settings. Recently,
the Ion Torrent personal genome sequencer has emerged as a tabletop personal genome sequencer that can be operated
in a time-efficient and cost-effective manner. In this study, we explored the technical feasibility to use multiplex PCR for
amplifying V(D)J recombination for IgH, directly from whole blood, then sequence the amplicons by the Ion Torrent
sequencer. The whole process including data generation and analysis can be completed in one day. We tested the method
in a pilot study on patients with benign, atypical and malignant meningiomas. Despite the noisy data, we were able to
compare the samples by their usage frequencies of the V segment, as well as their somatic hypermutation rates. In
summary, our study suggested that it is technically feasible to perform clinical monitoring of V(D)J recombination within a
day by personal genome sequencers.
Citation: Gao F, Lin E, Feng Y, Mack WJ, Shen Y, et al. (2013) Characterizing Immunoglobulin Repertoire from Whole Blood by a Personal Genome Sequencer. PLoS
ONE 8(9): e75294. doi:10.1371/journal.pone.0075294
Editor: James P. Brody, University of California, Irvine, United States of America
Received May 15, 2013; Accepted August 15, 2013; Published September 13, 2013
Copyright:  2013 Gao et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: ys2411@columbia.edu (YS); kaiwang@usc.edu (KW)
. These authors contributed equally to this work.
Introduction
Over 25 years ago, Susumu Tonegawa won the Nobel Prize in
Physiology & Medicine for discovering the genetics behind V(D)J
recombination, which refers to the genomic rearrangement of
variable (V), diversity (D), and joining (J) gene segments separated
by highly variable junction regions [1,2]. In human genome, the
immunoglobulin (Ig) loci contain many different V, D and J
segments, which are subject to rearrangement process during early
lymphoid differentiation. As a result of random V(D)J recombi-
nation, our body can produce enormous amounts of immune cells
each with a different Ig gene (mainly B cells). Together with
somatic hypermutation, the immune system can adapt to foreign
elements and produce antibody molecules to target/neutralize
antigens from bacteria, viruses, parasites and dysfunctional cells
such as tumor cells. Of note, several lymphoid malignancies in
humans are the direct results of monoclonal expansion of a specific
B-cell clone, so that the vast majority of B cells have identical
V(D)J recombination in patients with lymphoid malignancies [3].
Despite its importance in human disease and health, conven-
tional methods to measure V(D)J recombination have several
limitations to prevent detailed characterization of the immune
repertoire. Many earlier methods, such as restriction enzyme
digestion followed by Southern blotting or sizing of polymerase
chain reaction (PCR) products from Ig loci, were developed as
simple measures of the clonality of B cells, but they are too coarse
to reveal the intra-clonal heterogeneity. Later approaches, such as
multi-parameter flow cytometry, spectrotyping, or custom-de-
signed real-time PCR assays, are more quantitative and offer
higher resolution, but these methods are labor intensive and are
unable to offer sequence-level insights as to the exact V(D)J
recombination patterns in patients. Given the enormous amounts
of information content embedded within the immune repertoire,
sequence-level examination is expected to offer the most detailed
characterization of V(D)J recombination in human subjects.
With the development of massively parallel sequencing tech-
nologies, it is now feasible to assay V(D)J recombination by next-
generation sequencing, as a means to exhaustively profile the
immune repertoire in human subjects. One of the first such
studies, published in late 2009, measured and clinically monitored
human lymphocyte clonality by massively parallel pyrosequencing
using the Roche 454 sequencers [4]. In their study, DNA was
isolated from blood, and a series of redundant primers was used to
amplify IgH locus, and the resulting mixtures of amplicons were
sequenced by 454 sequencer. The advantage of using the 454
sequencer was its ability to generate longer sequencing reads that
PLOS ONE | www.plosone.org 1 September 2013 | Volume 8 | Issue 9 | e75294
potentially covers V(D)J recombination junction points. This
proof-of-concept study demonstrated the technical feasibility to
monitor malignancy by sequencing peripheral blood. Another
study also used similar techniques to reveal a complex pattern of
dynamic relationships among human T cell subsets [5]. These
studies relied on the 454 sequencer, due to its capability to
generate longer sequencing reads, which are more likely to cover
the V(D)J recombination junction points. However, other inves-
tigators have focused on Illumina Genome Analyzer that generates
only ,50 bp reads. For example, a group has developed a short-
read assembly strategy to first assemble 50 bp sequences and then
sample the CDR3 diversity in human T lymphocytes from
peripheral blood [6,7]. The data analysis involved in such strategy
is much less straightforward and may not be as deterministic as
454 sequencers, but it has the advantage of much higher
throughput and perhaps more readily accessible.
Given the limitations of previous studies, our goal is to evaluate
whether a new generation of personal genome sequencers can be
used to interrogate V(D)J recombination within a relatively short
period of time (within one day). Our study differs in several major
aspects: First, instead of relying on flow cytometry or magnetic
beads to isolate B cell populations from peripheral blood, we
attempted to assay DNA extracted directly from whole blood.
Second, we used genomic DNA rather than mRNA, as the
extraction of genomic DNA from blood is technically more
straightforward and genomic DNA is far less likely to be degraded
under clinical storage conditions. Third, we evaluated the usage of
Ion Torrent sequencer, an integrated semiconductor device that
performs non-optical DNA sequencing of genomes with a
turnaround time within hours [8]. It has slightly longer average
length of sequencing reads (typically ,200 bp) than the Illumina
sequencers used in previous studies, yet with much lower
Figure 1. Multiplex PCR reactions to amplify IgH V(D)J recombination on genomic DNA extracted from an EBV-transformed
lymphoblastoid cell line (monoclonal positive control). The combinations of two different PCR primer sets (A, B) are also shown in Figure 1a.
Predominant bands are observed for pools A & B with sizes around 330 bp and 280 bp (Figure 1b).
doi:10.1371/journal.pone.0075294.g001
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throughput (typically 1 million reads per run). We also note that
the new Illumina MiSeq platform has similar characteristics as Ion
Torrent. However, the turnaround time of personal genome
sequencers has been significantly shortened compared to Roche
454 or previous generation of Illumina sequencers. Despite slightly
shorter reads than Roche 454, these reads may be long enough to
interrogate V(D)J recombination directly without de novo assembly.
To evaluate our approach, we tested it on blood samples
collected from patients with meningiomas 2 the most common
brain tumors in the United States, and compared the sequence
data between patients with benign (grade I), atypical (grade II) and
malignant (grade III) tumors. Meningioma arises from the
membranous layers surrounding the central nervous system, thus
it is not subject to blood-brain barrier. Many previous studies have
already reported the presence of both humoral [9,10] and cellular
[11,12] immune responses in patients with meningiomas. Indeed,
one previous study has proposed that frequent antibody response
against specific antigens in benign meningiomas can serve as
diagnostic targets [9]. Therefore, meningiomas are well suited as
initial targets to test the technical feasibility of the technology, with
the added value of investigating immune differences between
tumor subtypes.
Results
Multiplex PCR Reactions to Explore V(D)J Recombination
on Igh Locus
Previous BIOMED2 study [13] has evaluated PCR primers for
detection of clonally rearranged immunoglobin genes. We
followed the protocol and used the same sets of PCR primers
(Table 1) to perform multiplex PCR reactions to capture
rearrangement of immune repertoire in the IgH locus. In
particular, we used two pools of PCR primer sets to amplify the
DNA fragments between different framework (FR) regions and JH
region (Figure 1a). To evaluate the effectiveness of the employed
PCR protocol, we first tested multiplex PCR amplification on an
EBV-transformed lymphoblastoid cell line, which served as a
monoclonal positive control. Interestingly, DNA electrophoresis
revealed single predominant bands for both VH_FR1– JH and
VH_FR2– JH pools with predominant fragment sizes around
330 bp and 280 bp, respectively (Figure 1b). For a fully
rearranged IgH locus, the genomic spans from VH FR1 to JH
are between 309 bp and 341 bp, depending on the exact VH
subtypes, whereas fragments between VH FR2 and JH are, 50 bp
shorter (Table 1). Thus the sizes of the amplified DNA fragments
from the two primer pools indicate that they are indeed products
Table 1. PCR primers for the IgH locus based on the
BIOMED2 primer sets.

















*Relative position is calculated from 59end of the primer sequence to the
involved RSS (recombination signal sequence).
doi:10.1371/journal.pone.0075294.t001
Figure 2. Two pools (A, B) of multiplex PCR reactions to amplify
IgH V(D)J recombination on genomic DNA extracted from
blood samples of three patients with different grades of
meningiomas (malignant –010_M, atypical –351_A, benign –
404_B). The bands with size around 280 bp in pool B (indicated in
arrows) were excised and purified for Ion Torrent sequencing.
doi:10.1371/journal.pone.0075294.g002
Next-Generation Sequencing of Immune Repertoire
PLOS ONE | www.plosone.org 3 September 2013 | Volume 8 | Issue 9 | e75294
from V(D)J recombination, most likely reflecting monoclonal
expansion for this lymphoblastoid cell line.
Inspired by the initial test run on the lymphoblastoid cells, we
applied the multiplex PCR reactions on genomic DNA extracted
directly from whole blood samples of three patients affected with
benign (grade I), atypical (grade II) or malignant (grade III)
meningiomas, respectively. Unlike single predominant bands
observed for lymphoblastoid cell line, DNA electrophoresis
revealed multiple bands for both primer pools (Figure 2). Of
note, without isolating mature B cells, the collected genomic DNA
may come from B cells with fully rearranged, partially rearranged
and intact IgH locus, as well as from other blood cell types. Based
on results on positive controls, we hypothesized that the ,280 bp
bands in VH-FR2– J pool (Figure 2) may have the fully
rearranged fragments, thus we excised and purified the bands
for next-generation sequencing.
Clonality of Immune Repertoire Revealed by V Gene
Usage
The raw FASTQ files from Ion Torrent sequencer were
mapped by BWA-SW [14] against hg19 genome assembly
(patched by replacing IgH sequences using the one from IMGT
[15]) or aligned against human_gl_V, human_gl_D and hu-
man_gl_J libraries from IgBLAST [16]. Our sequencing run
pooled additional amplicons (in addition to IgH) from the same
sample, so relatively small fraction of the reads can be mapped to
the IgH region. The BWA-SW mapping results of the three
meningioma samples revealed that between 15.0% and 38.2% of
the reads can be mapped to VH regions (Table 2). We however
noted that only very small fractions of reads (0.4% to 0.5%) can be
mapped to V-D or V-D-J junction points. In a parallel analysis
using the newly available IgBLAST tool, we also observed that the
malignant sample had a higher percentage of VH containing reads
(11.4%) compared to atypical or benign ones (4.9% and 5.6%,
respectively, Table 3). We also noted that 3% to 7% of the reads
contained V-D, V-J or V-D-J junctions. Thus, based on both
bioinformatics pipelines, V-D-J junction reads were not the
predominant form of reads, possibly due to sample processing
procedure to sonicate DNA fragments and the relatively short
sequence reads from the Ion Torrent sequencer (see Discussion
below).
We hypothesized that more severe tumors (grade II and III)
may have higher clonality in IgH populations, due to increased
humoral immune responses. To test this, we performed correlation
analysis to compare the V segment usage frequencies between
three tumor subtypes using BWA-SW mapping result (Figure 3).
However, we did not find apparent difference between the tumor
subtypes; that is, V segments that tend to be used more in one
tumor type also tend to be used more often in another tumor type.
Indeed, the Pearson’s correlation coefficients were greater than 0.9
in each pairwise comparison. Recognizing that we have evaluated
merely three samples, our results should be considered as
descriptive, and we caution that a definitive conclusion cannot
be drawn. However, we also observed a notable exception: the
usage of a particular VH gene, IgHV5-a, was sharply dropped in
atypical and malignant samples compared to the benign one
(Figure 3). Interesting to note, although the total fractions of
assigned V segment reads from IgBLAST were different from
BWA-SW, IgBLAST analysis also showed that IgHV5-a was
preferentially used in the benign sample: the fractions of reads
containing IgHV5-a in benign, atypical and malignant samples
were 0.856%, 0.007% and 0.005%, respectively. Therefore, results
from two analytical pipelines are largely concordant, despite
different sensitivity to assign reads.
Analysis of Somatic Hypermutation in Different
Meningioma Samples
Given the availability of individual sequence reads, we next
performed comparative analysis on somatic hypermutations
between three tumor subtypes. Following activation of naı¨ve B
cells, the IgH locus experiences a highly accelerated rate of
somatic mutation (increased by a factor of 105 to 106), so that the
mutation rate can reach 1 per 1,000 for each V gene base pair per
cell division, further diversifying the immune repertoire beyond
the genetic makeup of IgH. However, one potential confounding
factor is that Ion Torrent sequencer itself may introduce
sequencing errors, with observed error rate of 1.5% [17] and
1.7% [18] in different studies. Nevertheless, it is reasonable to




% of reads uniquely
assigned to VH
segment
% of reads uniquely
assigned to VH-DH
segment
% of reads uniquely
assigned to VH-DH-JH
segment
Total number of reads from
IGH targeted sequencing
404_B(benign) 84.5% 15.0% 0.2% 0.3% 294911
351_A(atypical) 79.1% 20.4% 0.2% 0.3% 71000
010_M(malignant) 61.4% 38.2% 0.2% 0.2% 19987
doi:10.1371/journal.pone.0075294.t002




% of reads containing
VH only
% of reads containing
VH-DH junction only
% of reads containing
VH-JH junction only
% of reads containing
VH-DH-JH junction
404_B(benign) 79.5% 5.6% 3.5% 4.0% 7.4%
351_A(atypical) 83.2% 4.9% 3.2% 2.8% 5.9%
010_M(malignant) 75.4% 11.4% 4.6% 5.0% 3.6%
doi:10.1371/journal.pone.0075294.t003
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assume that the same error rates will apply for all samples that
were sequenced at the same time under the same sample
preparation procedure. From the set of sequencing data, we
inferred the number of somatic hypermutations per sequencing
read, and compared the distribution between benign, atypical and
malignant samples. Although the overall distribution appeared to
be largely similar, we found apparent differences for reads with a
small number of mutations. Compared to atypical or malignant
meningioma, the benign tumor sample had higher fraction of
reads with only one or two somatic hypermutations (Figure 4a).
We acknowledge that a 1 bp difference could be due to germline
variants, but larger number differences in the same reads are more
likely to be due to somatic hypermutations. This observation may
indicate that more hypermutations tend to be accumulated in
more severe cancer subtypes, but our sample size is not enough to
make a definitive conclusion. Therefore, we report the results as
interesting observations only.
We next attempted to address an alternative possibility that the
observed differences in somatic hypermutation rates may be due to
difference in VH segment usage, given that IgHV5 is differentially
used in the benign tumor in comparison to atypical/malignant
samples (Figure 3). To test this, we removed the IgHV5 regions
from the somatic hypermutation analysis, yet we still obtained
similar set of results (Figure 4b). Therefore, our analysis
demonstrated that there might be differences in rates of somatic
hypermutations between different tumor samples. Again we
caution that this hypothesis requires much larger sample sizes
for further validation.
Discussion
In this study, we evaluated the technical feasibility of using Ion
Torrent personal sequencers to profile the immune repertoire,
particularly the IgH locus, from whole blood. Compared to
previous studies, our study did not separate B cells, used DNA
rather than RNA, applied standard multiplex PCR reactions, and
used a sequencer with one-day turnaround time including data
analysis. We demonstrated that it is technically feasible to use a
personal genome sequencer to interrogate V(D)J recombination.
However, the current turnaround time of a personal genome
sequencer is still not quick enough for this approach to be
considered as a point-of-care test, thus further reduction of
turnaround time is necessary. In addition to evaluation of
feasibility, we also made preliminary observation that IgH
hypermutation rates differ between patients with different severity
of the disease.
There are several technical details worth noting. First of all,
unlike all previous studies, our goal is not to interrogate patients
with lymphoid malignancies who already have clonal expansion of
B-cell populations, but to evaluate patients with meningiomas who
have humoral immune responses. Therefore, besides the ability to
evaluate technology, we also attempted to address an interesting
question whether patients with brain tumor differ in immune
responses. Due to small sample size, we cannot make a definitive
conclusion. Second, to simulate the situation of B-cell clonal
expansion, we have assayed a lymphoblast cell line, and confirmed
the efficiency of the BIOMED-2 primer sets on samples with
monoclonal expansion of B cells. We believe that this step is highly
important for our selection of bands to excise in the sequencing
experiments. Third, we obtained only ,150 bp average read
length from the Ion Torrent sequencer. Additionally, due to
technical limitations, our sample preparation procedure includes a
step to sonicate DNA fragments for the Ion Torrent run.
Unfortunately, the vast majority of reads do not cover the entire
V-D-J junction, complicating our analysis. With the development
of sequencers that can generate longer fixed-length reads such as
Illumina MiSeq (26300 bp, 15 Gb throughput) or HiSeq 2500
(26250 bp, 300 Gb throughput), this problem may be better
addressed by different personal genome sequencers in the future.
Fourth, the blood samples that we used were previously frozen
samples rather than freshly collected blood. Since DNAs are far
more stable than RNAs, our results demonstrated that frozen
blood samples could yield reliable results, which may not be
attainable using RNA-based procedures. Considering that DNAs
are much easier to process than RNAs, we expect that DNA-based
approaches will be more likely adopted in clinical settings.
Figure 3. Scatter plots of V segment usage frequencies between benign, atypical and malignant samples based on Ion Torrent
sequencing data. The IgHV5-a segment is represented in 10% of the IgH reads in the benign sample, yet ,1% in the atypical and malignant
samples.
doi:10.1371/journal.pone.0075294.g003
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One interesting observation from our study is that the benign
sample shows different usage statistics of VH segments and has
smaller somatic hypermutation rates, in comparison with the
atypical and malignant samples. For the former observation,
although the sequenced DNA fragments may include both
targeted V(D)J recombination events and contaminations (cap-
tured VH segments only account for 15% to 38% of total reads),
the data collected from meningioma patients with different grade
tumors revealed increased portion of VH-segment reads in the
total reads associated with malignancy of meningiomas. Such an
increase may reflect clonal expansion in malignant tumor. For the
latter observation, intuitively one would expect to see more
frequent somatic hypermutations with increased severity of
diseases, as a result of the immune system trying to adapt to
tumor antigens. Nevertheless, we still wish to stress that our study
is a pilot study and the observations are only restricted to three
samples, thus any conclusion requires further validation by studies
with larger sample size.
Figure 4. Comparison of somatic hypermutations in reads from IgH regions in three tumor subtypes. The benign tumor tends to have
less somatic hypermutations compared to atypical and malignant samples. (a) analysis on all available reads; (b) analysis after excluding IgHV5-a.
doi:10.1371/journal.pone.0075294.g004
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We expect that personal genome sequencers will increasingly
find their usage in clinical monitoring of patients and help guide
the selection of therapeutic regimens. The capability to generate
sequence data within days greatly helps clinical applications. In
our study, the use of whole blood rather than isolated B cells, the
use of DNA rather than RNA, and the use of Ion Torrent
sequencers are the keys to a relatively short turnaround time.
Therefore, with further optimization of protocols, this approach
may represent a viable option for clinical monitoring of patients
with lymphoid malignancies or other types of malignancies.
Finally, in the past decades, numerous biobanks with enormous
collections of frozen blood have been established and served as
resources to study the genetics of human diseases [19–22].
Revisiting these resources to decode the embedded immunoge-
nomic information using the latest sequencing platform may
provide novel insights into pathogenesis that were not considered
in typical genetic studies.
Materials and Methods
Sample Collection
We collected peripheral blood from patients with meningiomas
from the USC Brain Tumor Bank. All samples have extensive
phenotype information, including available consistency data and
brain perfusion data (an advanced MRI imaging technique
specifically used at USC that shows the blood flow patterns
around tumor tissues) to facilitate interpretation of results,
especially clonality measures. The study was approved by the
Institutional Review Board at the University of Southern
California. Informed written consent was obtained for all
participants prior to undergoing surgical tumor resection. All
patients presenting to Los Angeles County – USC Medical Center
or Keck Hospital of USC with benign, atypical or malignant
neoplasms of the brain were eligible participants.
Multiplex PCR Reactions
We directly extracted genomic DNA from frozen whole blood
using Qiagen blood DNA extraction kit, without isolating specific
cell populations. DNA concentrations were determined by a
Nanodrop spectrophotometer. To amplify V(D)J recombination in
IgH locus, we followed previous studies and used the BIOMED-II
primer sets [13]. We used EMD KOD Hot-Start PCR reaction kit
for amplification with 100 ng genomic DNA, 5 mL 10X reaction
buffer, 5 mL dNTP mix (2 mM each), 3 mL MgSO4 (25 mM),
2 mL of primer mix (10 mM each), 1 mL of KOD DNA
Polymerase in total 50 mL reactions. The PCR reactions started
with denaturing at 95uC for 2 minutes, followed by 40 cycles of
amplifications with 95uC for 20 seconds, 65uC for 10 seconds,
70uC for 1 minute, and finally 70uC for 2 minutes for product
repair. Genomic DNA from EBV-transformed lymphoblastoid
cells was used as a positive control for detecting V(D)J
recombination. Amplified PCR products were visualized using
DNA electrophoresis gel. The bands with expected size were
excised and purified using Qiagen MinElute gel Extraction kit for
sequencing.
Generation of Sequencing Data
We used the Ion Torrent 316 chip with the 200 bp kit for
generation of sequencing data on the Ion Torrent sequencer.
Briefly, we followed the manufacturer’s recommended library
construction procedures, sonicated the raw PCR products into
,250 bp fragments and then added adaptors for next-generation
sequencing.
Analysis of Sequencing Data
Unlike genome or exome sequencing, the nature of the V(D)J
sequencing data from IgH locus requires some adjustments for
reads mapping, as commonly used alignment software for
sequencing data requires a reference sequence that is sufficiently
similar to the sequences to be tested. As global alignment tools
such as BWA [23] and Bowtie (version 1.0) [24] do not have
optimal performance under default settings on reads spanning
V(D)J junctions, we used BWA-SW [14], a local alignment tool,
and found that it generally worked well to identify reads that
match to V, V-D or V-D-J segments. For comparison, we utilized
recently released IGBLAST mapping tool to explore V-(D)-J
recombination events from the sequencing data. For somatic
hypermutation analysis, we submitted the sequence data directly
to the IMGT/GENE-DB [25] web server with several batches
(due to the limitation of the web server to process large data sets),
and analyzed the results generated by the web server.
Accession Numbers
The raw sequencing data in the study are available for
download from Sequence Read Archive (http://www.ncbi.nlm.
nih.gov/sra) with project number PRJNA213114.
Acknowledgments
We are grateful for the patients with meningiomas for donating blood
samples for research purposes. We thank the USC Brain Tumor Bank for
providing whole blood samples and paired phenotype data. We thank
members of the Wang lab, Shen lab, and Columbia Genome Center for
helpful discussions and comments. Y.S. is supported by Department of
Systems Biology at Columbia University.
Author Contributions
Conceived and designed the experiments: YS KW. Performed the
experiments: FG EL YF. Analyzed the data: FG EL YF. Contributed
reagents/materials/analysis tools: WJM. Wrote the paper: FG YS KW.
References
1. Tonegawa S (1983) Somatic generation of antibody diversity. Nature 302: 575–
581.
2. Schatz DG, Swanson PC (2011) V(D)J recombination: mechanisms of initiation.
Annu Rev Genet 45: 167–202.
3. Shaffer AL, Rosenwald A, Staudt LM (2002) Lymphoid malignancies: the dark
side of B-cell differentiation. Nat Rev Immunol 2: 920–932.
4. Boyd SD, Marshall EL, Merker JD, Maniar JM, Zhang LN, et al. (2009)
Measurement and clinical monitoring of human lymphocyte clonality by
massively parallel VDJ pyrosequencing. Sci Transl Med 1: 12ra23.
5. Wang C, Sanders CM, Yang Q, Schroeder HW Jr, Wang E, et al. (2010) High
throughput sequencing reveals a complex pattern of dynamic interrelationships
among human T cell subsets. Proc Natl Acad Sci U S A 107: 1518–1523.
6. Freeman JD, Warren RL, Webb JR, Nelson BH, Holt RA (2009) Profiling the
T-cell receptor beta-chain repertoire by massively parallel sequencing. Genome
Res 19: 1817–1824.
7. Warren RL, Freeman JD, Zeng T, Choe G, Munro S, et al. (2011) Exhaustive
T-cell repertoire sequencing of human peripheral blood samples reveals
signatures of antigen selection and a directly measured repertoire size of at
least 1 million clonotypes. Genome Res 21: 790–797.
8. Rothberg JM, Hinz W, Rearick TM, Schultz J, Mileski W, et al. (2011) An
integrated semiconductor device enabling non-optical genome sequencing.
Nature 475: 348–352.
9. Comtesse N, Zippel A, Walle S, Monz D, Backes C, et al. (2005) Complex
humoral immune response against a benign tumor: frequent antibody response
against specific antigens as diagnostic targets. Proc Natl Acad Sci U S A 102:
9601–9606.
10. Heckel D, Brass N, Fischer U, Blin N, Steudel I, et al. (1997) cDNA cloning and
chromosomal mapping of a predicted coiled-coil proline-rich protein immuno-
genic in meningioma patients. Hum Mol Genet 6: 2031–2041.
Next-Generation Sequencing of Immune Repertoire
PLOS ONE | www.plosone.org 7 September 2013 | Volume 8 | Issue 9 | e75294
11. Pees HW, Seidel B (1976) Cell-mediated immune response of patients with
meningiomas defined in vitro by a [3H]proline microcytotoxicity test. Clin Exp
Immunol 24: 310–316.
12. Rossi ML, Cruz Sanchez F, Hughes JT, Esiri MM, Coakham HB (1988)
Immunocytochemical study of the cellular immune response in meningiomas.
J Clin Pathol 41: 314–319.
13. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, et al.
(2003) Design and standardization of PCR primers and protocols for detection of
clonal immunoglobulin and T-cell receptor gene recombinations in suspect
lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-
CT98–3936. Leukemia 17: 2257–2317.
14. Li H, Durbin R (2010) Fast and accurate long-read alignment with Burrows-
Wheeler transform. Bioinformatics 26: 589–595.
15. Lefranc MP, Giudicelli V, Ginestoux C, Jabado-Michaloud J, Folch G, et al.
(2009) IMGT, the international ImMunoGeneTics information system. Nucleic
Acids Res 37: D1006–1012.
16. Ye J, Ma N, Madden TL, Ostell JM (2013) IgBLAST: an immunoglobulin
variable domain sequence analysis tool. Nucleic Acids Res 41: W34–40.
17. Loman NJ, Misra RV, Dallman TJ, Constantinidou C, Gharbia SE, et al. (2012)
Performance comparison of benchtop high-throughput sequencing platforms.
Nat Biotechnol 30: 434–439.
18. Quail MA, Smith M, Coupland P, Otto TD, Harris SR, et al. (2012) A tale of
three next generation sequencing platforms: comparison of Ion Torrent, Pacific
Biosciences and Illumina MiSeq sequencers. BMC Genomics 13: 341.
19. Kaiser J (2006) Genetics. U.S. hospital launches large biobank of children’s
DNA. Science 312: 1584–1585.
20. Thornton H (2009) The UK Biobank project: trust and altruism are alive and
well: a model for achieving public support for research using personal data.
Int J Surg 7: 501–502.
21. Fan CT, Lin JC, Lee CH (2008) Taiwan Biobank: a project aiming to aid
Taiwan’s transition into a biomedical island. Pharmacogenomics 9: 235–246.
22. Nakamura Y (2007) The BioBank Japan Project. Clin Adv Hematol Oncol 5:
696–697.
23. Li H, Durbin R (2009) Fast and accurate short read alignment with Burrows-
Wheeler transform. Bioinformatics 25: 1754–1760.
24. Langmead B, Trapnell C, Pop M, Salzberg SL (2009) Ultrafast and memory-
efficient alignment of short DNA sequences to the human genome. Genome Biol
10: R25.
25. Giudicelli V, Chaume D, Lefranc MP (2005) IMGT/GENE-DB: a compre-
hensive database for human and mouse immunoglobulin and T cell receptor
genes. Nucleic Acids Res 33: D256–261.
Next-Generation Sequencing of Immune Repertoire
PLOS ONE | www.plosone.org 8 September 2013 | Volume 8 | Issue 9 | e75294
